Godavari Drugs

Godavari Drugs EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Godavari Drugs (530317.BO) as of Oct 17, 2026 is 85.25 M INR. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 118.28 M INR — a change of -27.92% (lower).

EBITDA

85.25 MINR

YoY

-27.92%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Godavari Drugs is 2026 85.25 M INR. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Godavari Drugs was 2025 118.28 M INR. It decreases by -27.92% lower compared to the previous year.

The Godavari Drugs EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2019
54.78 M INR
Jan 1, 2020
60.35 M INR
Jan 1, 2021
98.27 M INR
Jan 1, 2022
112.90 M INR
Jan 1, 2023
101.50 M INR
Jan 1, 2024
138.31 M INR
Jan 1, 2025
118.28 M INR
Jan 1, 2026
85.25 M INR
The Godavari Drugs EBITDA history
YEAREBITDAYoY
85.25 MINR-27.92%
118.28 MINR-14.49%
138.31 MINR+36.27%
101.50 MINR-10.09%
112.90 MINR+14.89%
98.27 MINR+62.82%
60.35 MINR+10.17%
54.78 MINR+35.59%
40.40 MINR-22.63%
52.22 MINR+16.16%
44.95 MINR-22.29%
57.85 MINR+213.57%
18.45 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Godavari Drugs Stock analysis

What does Godavari Drugs do? Godavari Drugs Ltd, based in Secunderabad, Telangana, manufactures active pharmaceutical ingredients (APIs) and intermediates for the global life science industry. The company operates facilities in Nanded, Maharashtra, producing APIs such as Ciprofloxacin HCl and Mefenamic Acid, along with intermediates like A D Lactone and 6 Mercaptopurine. It partners with multinational firms through contract manufacturing and holds active loan licenses for API production. Godavari Drugs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Godavari Drugs stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Godavari Drugs is 85.25 M INR in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Godavari Drugs changed from 118.28 M INR to 85.25 M INR, representing a -27.92% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Godavari Drugs since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Godavari Drugs historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Godavari Drugs

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Godavari Drugs